Blog

Quality Improvement Project vs Human Subject Research: What’s the Difference?

Quality improvement and human subjects research often intersect. Executive IRB Chair Sara Harnish discusses questions to differentiate the two.

Read Now
3 min. read
Read more
 
Blog

The Future of Phase I Oncology Studies

Oncology drugs in phase I trials are usually conducted on patients with cancer due to their inherent risk. Advarra IRB member Ran Goldman expands:

Read Now
4 min. read
Read more
 
Blog

Meeting the Challenges of Investigator-Initiated Trials

How does investigator-initiated research differ from other types of clinical research? Advarra IRB Chairperson Robert Romanchuk explains.

Read Now
6 min. read
Read more
 
Blog

The Challenge of Unproven Regenerative Stem Cell Therapies

Stem cell clinics with unproven treatments are on the rise in the US. Learn how the FDA is working to bring new stem cell therapies under federal oversight.

Read Now
7 min. read
Read more
 
Blog

Survey Best Practices for Process Improvement

Learn best practices of survey creation to help measure process improvement among stakeholders at an organization.

Read Now
5 min. read
Read more
 
Blog

Six Key GDPR Questions to Review

Questions still remain about GDPR and its applications. Have you considered these six key questions to ask within your organization?

Read Now
5 min. read
Read more
 
Blog

Can Ethics Review Catch Up to the CBD Craze?

CBD, a non-psychoactive cannabinoid, is experiencing a massive surge in popularity, but clinical research lags behind in verifying effective uses.

Read Now
4 min. read
Read more
 
Blog

Quorum/Kinetiq Acquisition & Integration:
What You Need to Know

On March 5, 2019, Advarra announced its acquisition of Quorum Review IRB and Kinetiq, the research and technology consulting division of Quorum.

Read Now
0 min. read
Read more
 
Blog

After the Compliance Date: Revised Common Rule FAQs (Or: Why We Cancelled Our February Webinar)

We have cancelled our webinar “After the Compliance Date: Revised Common Rule FAQs,” which was originally scheduled for February 28.

Read Now
0 min. read
Read more
 
Blog

Informed Consent Changes in the Revised Common Rule

If your research must comply with the revised Common Rule, you’ll need to update the way you write ICFs to meet the new requirements.

Read Now
4 min. read
Read more
 
Blog

Do I Need to Comply With the Revised Common Rule?

While many US researchers are aware of the coming Common Rule changes, not everyone is sure whether they will need to comply with the revised regulations.

Read Now
4 min. read
Read more
 
Blog

Reporting to the IRB: Serious Adverse Events (SAEs) in Drug Studies

Learn what the regulations say about IRB reporting requirements for serious adverse events and how some of the undefined “gray areas” can be addressed.

Read Now
5 min. read
Read more